PCA
EVLO

Peddock Capital Advisors’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Peddock Capital Advisors’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-183
Closed -$44K – 293
2020
Q4 		$44K Buy
+183
New +$22.6K 0.02% 173

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Peddock Capital Advisors's EVLO Position: Q1 2021 in Review

Peddock Capital Advisors sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q1 2021, closing a stake of 183 shares — an estimated $44K sold.

Peddock Capital Advisors first reported a position in EVLO in Q4 2020 and held it in 1 quarter. The position peaked at $44K in Q4 2020. 62 funds tracked by Wall St. Rank hold EVLO as of Q1 2021.

  • Peddock Capital Advisors reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Peddock Capital Advisors sold 183 Evelo Biosciences, Inc. Common Stock shares in Q1 2021, an estimated $44K.
  • Peddock Capital Advisors first reported a position in Evelo Biosciences, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Peddock Capital Advisors's Evelo Biosciences, Inc. Common Stock position peaked at $44K in Q4 2020.
  • 62 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q1 2021.

Based on Peddock Capital Advisors's 13F filing for Q1 2021, filed 17 May 2021.